Valeant (VRX) Shares Rise Following FY12 Outlook
Tweet Send to a FriendGet Alerts VRX Hot Sheet
Price: $74.67 -0.2%
EPS Growth %: +31.3%
Financial Fact:
Gain on early extinguishment of debt: 0
Today's EPS Names:
TARO, SENEA, UQM, More
EPS Growth %: +31.3%
Financial Fact:
Gain on early extinguishment of debt: 0
Today's EPS Names:
TARO, SENEA, UQM, More
Trade VRX Now!
Shares of Valeant Pharma (NYSE: VRX) have just turned positive following an 8-K filing which offers some insight into FY12 results.
Valeant expecting FY12 sales of $3.1-$3.4 billion and cash EPS of $3.95-$4.20. The company expects adjusted cash flow from operations to be greater than $1.2 billion.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Valeant expecting FY12 sales of $3.1-$3.4 billion and cash EPS of $3.95-$4.20. The company expects adjusted cash flow from operations to be greater than $1.2 billion.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Valeant Pharmaceuticals Announces 2013 Annual Meeting Results
- Pandora (P) Pops Higher on Q1 Results; Expands Listener Base by 2.5M Subs
- Highway Holdings (HIHO) Surges, Halted on $400K Per Year Order
Create E-mail Alert Related Categories
Guidance, Momentum Movers
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
